Roivant Sciences revenue and financials

ROIV · NASDAQ · USD

$35.53Change from previous close: −0.70%Absolute change: −$0.25

Close · October 6, 2026

In the fiscal year ended March 2026, Roivant Sciences reported revenue of $8.26M (−71.57% year over year). The net loss was $299.77M.

Annual revenue · 2026: $8.26M
  1. $23.8M2021
  2. $55.29M2022
  3. $31.53M2023
  4. $32.71M2024
  5. $29.05M2025
  6. $8.26M2026

Fiscal year ending in March. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
−71.57%
FY to Mar 2026 vs FY to Mar 2025
Net margin
-3,629.2%
FY to Mar 2025: -592.0%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Quarterly
ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue1.42.52.01.62.27.69.04.58.09.015.63.6
Cost of revenue202199166164153145140141119106100115
Gross profit-201-197-164-163-151-137-131-137-111-96.9-84.7-111
Selling, general and administrative16617317513013222813219693.099.710188.6
Research and development202199165165153———————
Operating income-366-370-339-292-283-365-263-333-204-197-186-200
EBIT-366-370-339-292-283-365-263-333-204-197-186-200
EBITDA-366-369-338-291-282-357-262-331-202-183-183-194
Pre-tax income-295454-290-159-269-203-235-224-19.6-1015,154-241
Income tax-4.098.423.37.04.649.3-25.612.512.0-5.822.43.2
Net income-190303-266-114-223-206169-23095.3-1515,096-304
Net income to common shareholders-190303-266-114-223-206169-23095.3-1515,096-304
Basic EPS-0.260.43-0.38-0.17-0.33-0.290.23-0.310.13-0.196.37-0.40
Diluted EPS-0.260.28-0.38-0.17-0.33-0.290.23-0.310.13-0.196.03-0.40
Average shares (basic)721702697681680707723735736803801770
Average shares (diluted)721812697681680707723735782803844770